Additional information regarding these results and other relevant information is included in the notes to the financial statements in “Item 18. Financial Statements”, which are included in InflaRx’s ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

Hong Kong-based biopharma company Akeso (HKEX: 9926) announced that its global first-in-class PD-1/VEGF bispecific antibody, ...

The company expects the final trial visits and the collection of data to take place by the second quarter of this year.

A good update was also provided here a few months ago, whereby the independent data monitoring committee (IDMC) already recommended dosing of the second cohort of this study. As I stated in the ...

The policy mandates the formation of a State Data Steering Committee (SDSC), which will coordinate and monitor the implementation of this policy in close collaboration with all departments and ...

An independent data monitoring committee (iDMC) that regularly reviews all of the data from the trial recently held their scheduled meeting and made a recommendation to modify the trial design. To cut ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground ... is combing through HUD data to identify undocumented immigrants and then share that data with the ...